Key result
Novel DREAM ligand IQM-266 inhibits and slows inactivation of A-type potassium currents in rat neurons.
Why the study?
Small molecules binding DREAM modify KV4 potassium channel function and regulation of IA currents, prompting the search for novel DREAM ligands.
IQM-266 is identified as a novel DREAM ligand that modulates KV4.3/DREAM channels and neuronal A-type potassium currents, providing a new chemical tool to study DREAM's physiological role and neuronal excitability.
Answers are grounded in this paper and cite their sources.
New probe for DREAM function in neurons; leaves open any clinical relevance or therapeutic translation.
DREAM/KChIP3/calsenilin is a neuronal calcium sensor with multiple functions, including the regulation of A-type outward potassium currents (IA). This effect is mediated by the interaction between DREAM and KV4 potassium channels and it has been shown that small molecules that bind to DREAM modify channel function. A-type outward potassium current (IA) is responsible of the fast repolarization of neuron action potentials and frequency of firing. Using surface plasmon resonance assays and electrophysiological recordings of KV4.3/DREAM channels, we have identified IQM-266 as a DREAM ligand. IQM-266 inhibited the KV4.3/DREAM current in a concentration-, voltage-, and time-dependent-manner. By decreasing the peak current and slowing of the inactivation kinetics, IQM-266 led to an increase in the transmembrane charge (QKv4.3/DREAM) at a certain range of concentrations. The slowing of the recovery process and the increase of the inactivation from the closed-state inactivation degree are consistent with a preferential binding of IQM-266 to a pre-activated closed state of KV4.3/DREAM channels. Finally, in rat dorsal root ganglion neurons, IQM-266 inhibited the peak amplitude and slowed the inactivation of IA. Overall, the results presented here identify IQM-266 as a new chemical tool that might allow a better understanding of DREAM physiological role as well as modulation of neuronal IA in pathological processes.
No takes yet. Share an insight, caveat, or question.
Peraza et al. (2019) studied Neuronal A-type outward potassium currents. IQM-266 was evaluated on KV4.3/DREAM current inhibition and modulation of IA. IQM-266 was identified as a novel DREAM ligand that inhibits the peak amplitude and slows the inactivation of A-type outward potassium currents in rat dorsal root ganglion neurons.
Synapse has enriched 10 related papers. Consider them for comparative context: